Phase 2 Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to follow the study procedures throughout the trial
- People aged 18 to 74 years old at the time of signing the consent form
- People who have been clinically diagnosed with centre-involving diabetic macular oedema (a specific type of swelling in the central part of the retina related to diabetes)
- People whose best corrected vision score (measured using a standard eye chart with glasses or contact lenses if needed) in the eye being studied falls between 24 and 73 letters
Who may not be able to join:
- People who have any other eye conditions in the studied eye — apart from diabetic macular oedema — that the investigator believes could affect vision improvement or would need treatment during the study to prevent or treat vision loss
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xiaorong Li, Professor, Tianjin Medical University Eye Hospital
Phone: +86-021-58206061
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety and tolerability after FT-003 injection
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.